Shares of Microbot Medical Inc (NASDAQ:MBOT) traded up 10.4% on Monday . The company traded as high as $0.87 and last traded at $0.85. 522,733 shares changed hands during mid-day trading, a decline of 45% from the average session volume of 944,615 shares. The stock had previously closed at $0.77.

A number of analysts have recently weighed in on the stock. ValuEngine upgraded shares of Microbot Medical from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd. Ladenburg Thalmann Financial Services assumed coverage on shares of Microbot Medical in a report on Wednesday, January 31st. They issued a “buy” rating and a $1.75 target price on the stock.

The stock has a market cap of $32.30, a price-to-earnings ratio of -1.23 and a beta of -0.39.

In related news, Director Yoseph Bornstein sold 45,000 shares of the company’s stock in a transaction dated Tuesday, November 21st. The shares were sold at an average price of $1.21, for a total transaction of $54,450.00. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders have sold a total of 272,990 shares of company stock worth $291,894 over the last quarter. 31.83% of the stock is currently owned by insiders.

An institutional investor recently raised its position in Microbot Medical stock. Vanguard Group Inc. boosted its position in shares of Microbot Medical Inc (NASDAQ:MBOT) by 252.2% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 159,992 shares of the biotechnology company’s stock after purchasing an additional 114,561 shares during the period. Vanguard Group Inc. owned about 0.43% of Microbot Medical worth $228,000 as of its most recent SEC filing. 4.67% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: “Microbot Medical (MBOT) Trading 10.4% Higher” was first posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be viewed at

Microbot Medical Company Profile

Microbot Medical Inc, formerly StemCells, Inc, is a medical device company. The Company specializes in the researching, designing, developing and commercializing transformational micro-robotic medical technologies leveraging the artificial and natural lumens within the human body. It is engaged in developing its two product candidates: the Self Cleaning Shunt (SCS) for the treatment of hydrocephalus and normal pressure hydrocephalus (NPH), and TipCAT, a self-propelling, semi-disposable endoscope that the Company is developing for use in colonoscopy procedures.

Receive News & Ratings for Microbot Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Microbot Medical and related companies with's FREE daily email newsletter.